VTC Hosts LTBI R01 Meeting
The Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our LTBI R01 project “Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts” (NIH R01AI147765). The event, which took place between March 21st and 22nd, and included presentations about ongoing research and data findings, working group sessions, and breakout meetings.
VTC hosts visitors from Brazil, South Africa, UW for grant project meeting
Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our LTBI R01 project “Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts” (NIH R01AI147765). The event, which took place between May 31st and June 2nd, included presentations about ongoing research and initial data, working group sessions, and breakout meetings.
Results Published: Randomized Trial for Self-administered vs DOT Once-Weekly Isoniazid and Rifapentine Treatment of Latent TB Infection
Results from the iAdhere trial conducted through the TB Trials Consortium have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Enrollment sites were located in the US, Spain, Hong Kong, and South Africa; Vanderbilt and the Metro Nashville Health Department participated in enrollment.